The appearance of hypophysitis in 3 checkpoint-treated patients (2 with ipilimumab, 1 with CD-40 monoclonal antibody) who did not have preexisting hypopituitarism suggests that indoximod helped to break tolerance after they were primed with the prior therapy months before going on this study. The gene discussed is CD40; the disease is hypophysitis.